I am excited to share with you the latest news in our journey to develop a treatment for x-linked hypohidrotic ectodermal dysplasia (XLHED). EspeRare, a not-for-profit drug developer based in Switzerland, is picking up where Edimer Pharmaceuticals left off! EspeRare is exploring the possibility of re-launching the development of ER-004 (formerly known as EDI200) as a treatment for babies affected by XLHED. They are looking to start a phase II clinical study where ER-004 would be administered to babies “in utero”.

 

This is incredible news for all of us! However, this relaunch is still at an early stage. EspeRare is conducting a study to ensure that its plan is feasible and suited to our community’s needs.  At this point, the main hurdles to overcome are developing both a regulatory and funding plan to take this project forward.

We are working closely with EspeRare during this key phase and doing all we can to help make it a success. We are thrilled with this development but understand it’s early in the process!

What is ER004?

ER004, is a synthetic form of Ectodysplasin A (EDA), the protein missing in XLHED during development. Through the years, you have heard us call it APO200 when Apoxis was developing it, then EDI200 when Edimer was involved and now it’s called ER-004.  It is the first and only therapy developed for XLHED. This is cutting edge research and a highly innovative therapy.

Timmy, Drew and Liam are three of the babies who participated in the Newborn XLHED Clinical Trial from 2013-2015.

Edimer’s first study successfully demonstrated the therapy to be well tolerated. In their follow-up study, the XLHED Newborn Clinical Trial, the treatment did not correct the XLHED symptoms in the newborn boys who received it, as we had hoped. At that point, Edimer stopped the development and closed its operations. All of us in the ectodermal dysplasias community were disheartened by the setback. But not for long.

Babies treated in utero
Maarten and Linus are sweating normally after receiving ER-004 in utero.

Last December, we shared the promising news that Prof. Holm Schneider in Germany had treated three babies prenatally with ER-004. It’s still early to fully understand how well the treatment has worked. However, to date, the babies are able to sweat normally and have not had any respiratory-linked hospitalizations. They may have other positive outcomes yet to be assessed. Prof. Holm Schneider will  share these results at the Family Conference in July. Isn’t that amazing! It looks like giving the replacement protein during pregnancy versus to newborn appears to markedly improve its effectiveness.

Research is at a Critical Point

Preliminary results show the potential to alleviate two symptoms of the most common ectodermal dysplasia. But we need your help to fund this project and others.

Contribute to Groundbreaking Research

EspeRare’s Plan

EspeRare plans to build on Prof. Schneider’s early success and administer ER-004 in utero to boys affected by XLHED in a clinical trial to assess if this therapy works. First, EspeRare has started a dialogue with the regulatory authorities to understand if they will allow this ground-breaking clinical trial. If the regulatory path and funding are secured, then the trial could start in 2018 in the European Union (EU) with Prof. Schneider as principal investigator. They plan to expand the study to the United States after interim positive results.

The primary objective of this trial is to assess ER-004’s ability to restore the babies’ ability to sweat. ER-004 would be administered through two injections a few weeks apart during the third trimester of pregnancy. This means that this could be a single course of treatment that could have life-long effects – if successful!

Prof. Holm Schneider will be a principal investigator.

The Players

While EspeRare is new to the world of XLHED research, they are talking and working with people and organizations like the NFED. EspeRare has been working with Neil Kirby, former Edimer CEO, on transitioning this project. They have identified Prof. Schneider, who was a part of the XLHED Newborn Clinical Trial and treated the three babies, to be the principal investigator. Also on board is Pascal Schneider, who was one of the researchers who engineered ER-004 (called APO200 at the time) in the lab with NFED funding!

But, First Things First

EspeRare needs to understand if the XLHED community is interested in such a therapy. This is where you come in. Soon, we will ask families affected by XLHED to complete a survey for EspeRare. Watch for those details to be coming very soon! We will need you to act quickly.

We hope you share our renewed hope in creating a treatment for our families with XLHED. We still have a long way to go and a lot of work to do. We are committed to advancing this important work and hope you are, too.

Onward!

Together, we can make this happen!

10 comments on “XLHED Treatment: From Setback to Renewed Hope”

  1. 1
    Lisa on July 7, 2017

    This is fantastic news. What about the other forms?

    1. 2
      Jodi Edgar Reinhardt on July 7, 2017

      Hi, Lisa. This project only focuses on the x-linked form of hypohidrotic ectodermal dysplasia (HED). The other forms of HED are caused by other genes. We are hopeful that one day we will have some kind of treatments for those forms, too. ~ Jodi, NFED

  2. 3
    Bettina Masulli on July 7, 2017

    Hi this is great news!!!! What about this twin teeth?? Did they develop already any?

    1. 4
      Jodi Edgar Reinhardt on July 7, 2017

      Hi, Bettina. Dr. Schneider will be presenting an update at the Family Conference on July 22nd. We look forward to hearing what he has to say about the twin’s teeth at that time! Stay tuned. ~ Jodi, NFED

  3. 5
    James A. Finch on July 7, 2017

    Is there funding potential from the 21st Century Cures Act? If not, maybe there is potential funding for the more life threatening forms of ED where there is significantly more pain, grief and suffering. Back more-so to the topic of the article. This is excellent news. For the EU and the rest of the World, this will help boost confidence for those affected to be able to breed and provide the financial incentive to have a marketable versus bio-equivalent option… of which I have not read where bio-equivalent (i.e. extract of EDA from donor then transfused) options have been tested as they seem feasible to me. However, most communities do not have specialized treatment centers for bio-equivalent options other than blood transfusions and organ transplants so a commercial marketable treatment would be beneficial for more main stream operations accessibility. With sweating being the primary condition to impact, I wonder what the trimester for vectoring in the EDA will impact hair development. This seems to be an interesting topic Pascal was working on in another research project if I recall correctly… prenatal hair growth treatment. So, first the dental and thermal exchange genetic condition correction and then seems hair treatment then hair treatment regionally would be value added for some communities that worry about that stuff. Maybe oppositely, even antagonist or blockers for the hairiest breeds could have a marketable potential. First things first… impacting the inability to sweat and develop teeth.

  4. 6
    Debbie Reed on July 7, 2017

    This brings tears of joy and HOPE for my grandchildren and so many families! Thank you! Thank you! Thank you! Can’t wait to learn more!

  5. 7
    Surender lamba on July 8, 2017

    After my son was born n I came to know he was having this issue of sweat hair n teeth….I was so sad n then I realised how important it is to be a ‘normal’ healthy person…
    It’s realy a ray of hope for us if next generation is treated to live a normal life……Thank you so so so much doctors n there whole team for giving us hope

  6. 8
    Kristina Crane on July 9, 2017

    Let us know how we can help. We participated in some of first round studies and are ready for the next. It will take all of us and this is so exciting for our children.

    1. 9
      Jodi Edgar Reinhardt on July 9, 2017

      Hi, Kristina. Thrilled to hear you want to help! We will be asking all families affected by XHLED to complete a survey in the coming weeks for EspeRare. So, be on the lookout for that. You are also right in that it will take all of us. The NFED started the research for XLHED back in the late 80s. Families have been a driving force at every step in the journey. Together, we will do this! – Jodi, Director, Marketing and Communications, NFED

  7. 10
    inspirational freedom quotes on July 9, 2017

    Everything is very open with a clear description of the issues.

    It was really informative. Your site is useful. Thanks for sharing!

Leave a Reply

Your email address will not be published. Required fields are marked *